

Berichtstitel: Studien Administration-Liste

Datum und Uhrzeit der Ausführung: 03.06.2024 09:56:20 Central European Summer Time

Ausgeführt von: May Jane Erne (I0326428)

Tabellenname: u_contract_management

Abfragebedingung: Eröffnet von ist May Jane Erne (I0326428) .or. DLF Administrator ist May Jane Erne (I0326428) .or. Studententeam ENTHÄLT (May Jane Erne (I0326428)) .or. Studienleiter ist May Jane Erne (I0326428) AND Status in (Abgeschlossen, Abgebrochen)

Sortierreihenfolge: SN-ID in aufsteigender Reihenfolge

24 Studien Administrationen

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Abgeschlossen	1558	STD0002491	035/08	Nikhil Yawalkar (I0026599)		Identification of inflammatory and immune cell function in psoriasis.	31.08.2014	29.01.2024
Abgeschlossen	3561	STD0004461	2017-00185	Pierre de Viragh (I0083049)		Elastikafaser-Färbung zur histologischen Unterscheidung von Lichen planopilaris und Fibrosierender Alopezie.	31.03.2018	29.06.2021
Abgeschlossen	3570	STD0004469	2017-01776	Dagmar Simon (I0068240)	JAHN	JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib an Adult Patients with Atopic Dermatitis.	28.02.2018	31.12.2023
Abgeschlossen	3608	STD0004501	2017-01216	Helmut Beltraminelli (I0084818)		Comparative analysis of immunohistochemical findings in patients suffering from leg ulcers.	28.02.2019	30.12.2021

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Abgeschlossen	3656	STD0004542	2018-00391	Dagmar Simon (10068240)		Characteristics of dermatological patients with (hyper-) eosinophilia.	31.05.2018	30.12.2022
Abgeschlossen	3675	STD0004560	2017-02155	Nikhil Yawalkar (10026599)	Aprescalp	A phase 4 multicenter, randomized, placebo-controlled study evaluating the effect of Apremilast on pruritus and quality of life of patients with moderate-to-severe scalp Psoriasis.	30.11.2018	30.09.2022
Abgeschlossen	3677	STD0004562	2018-00174	Robert Hunger (10060960)		Neovascularization is in cutaneous warts.	31.07.2018	31.12.2022
Abgeschlossen	3780	STD0004654	2018-00489	Dagmar Simon (10068240)	BREEZE-AD4	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine.	30.09.2018	31.12.2023

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Abgeschlossen	3950	STD0004811	2019-00313	Nikhil Yawalkar (10026599)	PSO systemic therapy	The use of apremilast and biological therapies for the treatment of psoriasis.	31.03.2019	01.03.2024
Abgeschlossen	3998	STD0004852	2018-02163	Robert Hunger (10060960)	SUNSHINE	CAIN457M2301 - A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa (SUNSHINE).	30.04.2019	29.04.2022

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Abgeschlossen	4122	STD0004962	2018-02382	Dagmar Simon (10068240)	C3291037	A PHASE 3B/4, MULTICENTER , RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTE ROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TOLERABILITY OF CRISABOROL E OINTMENT, 2% IN PEDIATRIC AND ADULT SUBJECTS (AGES 2 YEARS AND OLDER) WITH MILD TO MODERATE ATOPIC DERMATITIS.	31.03.2020	30.03.2022
Abgeschlossen	4192	STD0005027	2019-00850	Nikhil Yawalkar (10026599)	VALUE	Multi-Country Prospective Observational, Cohort Study of Patients with Moderate to Severe Chronic Plaque Psoriasis.	31.01.2020	30.03.2025

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Abgeschlossen	4234	STD0005058	2019-00620	Robert Hunger (I0060960)	Teledermatolog y in the Follow- Up of Patients wi	Randomized Open-Label Trial Comparing Teledermatolog y vs. Face-to- Face Consultation in the Follow-Up of Patients with Mild-to- Moderate Acne.	31.05.2020	31.12.2022
Abgeschlossen	4299	STD0005113	2019-02261	Dagmar Simon (I0068240)	LPS15497	A randomized double-blind placebo- controlled study evaluating the effect of dupilumab on sleep in adult patients with moderate to severe atopic dermatitis.	30.04.2020	27.02.2022
Abgeschlossen	4519	STD0005290	2020-01275	Simone Cazzaniga (I0309913)	AI-derma1	Prediction and pattern analysis of dermatological emergency patient disposition with deep-learning artificial neural networks.	30.09.2020	29.09.2021
Abgebrochen	4670	STD0005405	2020-00987	Kristine Heidemeyer (I0081272)	Er.YAG in lupus scars	Within-subject, investigator initiated, single- blind, singlecentre, randomized clinical trial investigating the efficacy of fractional Er:YAG laser in lupus erythematosus scars.	31.03.2021	30.12.2023

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Abgeschlossen	4695	STD0005421	2020-02411	Kristine Heidemeyer (I0081272)	HIFU in AK	Project Title: High-frequency (20 MHz) high-intensity focused ultrasound (HIFU) in actinic keratosis: a retrospective study.	31.01.2021	30.12.2021
Abgeschlossen	4716	STD0005437	2020-00727	Robert Hunger (I0060960)	HS0003	A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa.	31.03.2021	30.07.2022
Abgeschlossen	4757	STD0005474	2020-02530	Dagmar Simon (I0068240)	RD.06.SPR.203065	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis.	31.03.2021	30.08.2023
Abgeschlossen	4725	STD0005565	2020-00581	Kristine Heidemeyer (I0081272)	Tattoo	Medizinische Komplikationen von Tätowierungen.	31.03.2021	30.12.2021

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Abgeschlossen	5005	STD0005622	2021-01790	Dagmar Simon (10068240)	CLOU064A230 2	A Phase 3 study of efficacy and safety of remibrutinib in the treatment of chronic spontaneous urticaria in adults inadequately controlled by H1-antihistamines	01.10.2021	31.10.2023
Abgeschlossen	4843	STD0005658	2021-00004	Dagmar Simon (10068240)	B7451064	B7451064 - ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS	01.01.2021	30.06.2023
Abgeschlossen	4903	STD0005741	2021-01405	Laurence Feldmeyer (10310392)		Evolution of the overall survival of patients with Sezary syndrome over the 1998-2020 period and its association with the early use of therapeutic monoclonal antibodies.	15.09.2021	31.12.2023

Status	DLF Studien-Nr.	▲ SN-ID	BASEC-Nummer	Studienleiter	Akronym	Studientitel	Studienbeginn	Studienende
Abgebrochen	5274	STD0005821	2022-00700	Dagmar Simon (10068240)	RD.06.SPR.203 890	A Double-Blind, Placebo- Controlled, Randomized Study to Assess the Durability of Effect and Safety of Nemolizumab for 24 Weeks in Subjects with Prurigo Nodularis	01.01.2023	31.12.2023